Top 50 Psychedelics Companies that Have Raised the Most Money

The past decade has seen a meteoric rise in the number of psychedelic-based companies. As research advances and regulations begin to ease, companies are raising hundreds of millions of dollars to make psychedelic treatments a viable option within the global healthcare landscape.

Both the healthcare and pharmaceutical industries are showing great interest in harnessing the powers of psychedelic compounds such as psilocybin, LSD, MDMA, DMT, and ketamine. The potential benefits of psychedelic compounds appear vast, with the potential to treat various conditions, such as depression, post-traumatic stress disorder, and addiction. Psychedelic companies add accessibility to these benefits through products such as on-body delivery systems, extracts, pharmaceuticals, guided psychotherapy sessions, and many more.

The boom in the psychedelic industry is still in the early innings. As these companies continue to receive funding and develop viable psychedelic solutions, they have the potential to become a mainstay in the medical industry. Here are the top psychedelic companies that raised the most money to date:

Founded: 2018
Location: Dublin, Ireland
Market Cap: $559.2m (Public)
What the company does: GH Research is focused on developing treatments for psychiatric conditions using the serotonergic psychedelic 5-MeO-DMT. The treatments seek to regulate nervous system function through agonist action on serotonin receptors. 

Learn more about GH Research on their website.

Founded: 2018
Location: Munich, Germany
Market Cap: $467.0m (Public)
What the company does: ATAI Life Sciences is a psychedelic company developing evidence-based psychedelic therapies to treat psychiatric disorders such as depression, anxiety, and schizophrenia. ATAI is also an investor in the space, providing funds to other psychedelic companies to accelerate development. 

Learn more about ATAI Life Sciences on their website.

Founded: 2016
Location: Altrincham, Chesire
Market Cap: $444.3m (Public)
What the company does: Compass Pathways is designing psychedelic-based mental health therapies for a variety of disorders. Their primary product is the COMP360 psilocybin therapy targeting treatment-resistant depression. 

Learn more about Compass Pathways on their website.

Founded: 2001
Location: Melbourne, Australia
Market Cap: $224.9m (Public)
What the company does: Incannex has designed six clinical programs curated to “Alleviate Human Suffering”. The programs use a combination of psychedelic-based medicines and psychotherapy to address a variety of disorders, such as lung inflammation, sleep apnea, and rheumatoid arthritis. 

Learn more about Incannex Health on their website.

Founded: 2019
Location: Boston, Massachusetts
Market Cap: $118.0m (Private)
What the company does: Delix is utilizing the recent discovery of neuroplasticity therapeutics called pyschoplastogens to develop treatments for selective rewiring of neural circuits. Their non-hallucinogenic therapeutics are designed to be deployed at scale. 

Learn more about Delix Therapeutics on their website.

Founded: 2019
Location: Beckley, Oxfordshire
Market Cap: $114.2m (Private)
What the company does: Beckley Psytech utilizes advanced digital tools and a deep network of specialists to develop psychedelic treatments that fundamentally change how psychiatric and neurological conditions are treated. Berkley Psytech is led by Lady Amanda Feilding, also known as the “hidden hand”, who is renowned as one of the leading pioneers of psychedelic science. 

Learn more about Beckley Psytech on their website.

Founded: 1987
Location: New York, New York
Market Cap: $102.4m (Public)
What the company does: Seelos Therapeutics is developing psychedelic and non-psychedelic-based therapies addressing the unmet needs of patients with central nervous system disorders such as Lou Gehrig’s disease and Parkinson’s disease. 

Learn more about Seelos Therapeutics on their website.

Founded: 2019
Location: New York, New York
Market Cap: $97.7m (Public)
What the company does: MindMed uses psychedelic-based therapies to deliver treatment in fields such as addiction, pain, and psychiatry. Their drug portfolio includes medicines (MM-120 and MM-402) derived from compounds such as MDMA, DMT, and Psilocybin.

Learn more about MindMed on their website.

Founded: 2019
Location: Toronto, Ontario
Market Cap: $72.4m (Public)
What the company does: Cybin is engineering proprietary drug discovery platforms, drug delivery systems, and psychedelic treatments for mental health disorders. Their primary psychedelic development programs address depression, alcohol addiction, and anxiety. 

Learn more about Cybin on their website.

Founded: 2019
Location: Vancouver, British Columbia
Market Cap: $66.9m (Public)
What the company does: Numinus Wellness provides a holistic approach to mental healthcare through ketamine-assisted psychotherapy, psychedelic medicine, and mindfulness approaches. 

Learn more about Numinus Wellness on their website.

Founded: 2012
Location: Vaughan, Ontario
Market Cap: $65.2m (Public)
What the company does: Revive Therapeutics utilizes cannabis and psilocybin-based therapies targeting rare inflammatory conditions such as liver disease. 

Learn more about Revive Therapeutics on their website.

Founded: 2020
Location: San Francisco, California
Market Cap: $57.2m (Private)
What the company does: Osmind is a medical technology platform that aids in the development of psychedelic-based medicines and research. Osmind provides technical solutions to healthcare providers using medications and treatments such as TMS, Ketamine, SPRAVATO, and other psychedelic compounds. 

Learn more about Osmind on their website.

Founded: 2011
Location: Toronto, Ontario
Market Cap: $44.8m (Public)
What the company does: Mindset Pharma is developing psychedelic compounds for the treatment of psychiatric and neurological disorders. With four families of treatments, drug development primarily consists of synthesized psilocybin and DMT.

Learn more about Mindset Pharma on their website.

Founded: 2015
Location: London, England
Market Cap:  $43.5m (Public)
What the company does: Small Pharma is a pharmaceutical development company using DMT-based therapies for fast-acting antidepressant treatments.

Learn more about Small Pharma on their website.

Founded: 2019
Location: New York, New York
Market Cap: $29.6m (Private)
What the company does: Gilgamesh is harnessing the therapeutic capabilities of psychedelic compounds to develop innovative treatments for various mental illnesses. They use their deep medical expertise and AI-powered platform to increase efficiencies across the drug development process. 

Learn more about Gilgamesh Pharmaceuticals on their website.

Founded: 2020
Location: Vancouver, British Columbia
Market Cap: $24.9m (Public)
What the company does: Optimi Health accelerates the development of psychedelic science by supplying pharmaceutical-grade natural and synthetic psilocybin compounds.

Learn more about Optimi Health on their website.

Founded: 2019
Location: Issaquah, Washington
Market Cap: $22.0m (Private)
What the company does: CaamTech promotes the overall well-being of consumers through psychedelic formulations containing multiple psychoactive compounds from LSD, psilocybin, and DMT.  

Learn more about CaamTech on their website.

Founded: 2017
Location: Vancouver, British Columbia
Market Cap: $16.1m (Public)
What the company does: Bright Minds is using psychedelic-based drugs to treat the central nervous system and mental health disorders. Their treatments are primarily centered on optimizing the relationship between serotonin and the brain, seeking to regulate dysfunction in the serotonin system. 

Learn more about Bright Minds BioSciences on their website.

Founded: 2020
Location: San Francisco, California
Market Cap: $15.7m (Private)
What the company does: Journey Colab is developing synthetically-derived psychedelic therapeutics for addiction treatment. Their flagship product is the synthetic Mescaline HCI used for the treatment of alcohol addiction. 

Learn more about Journey Colab on their website.

Founded: 2002
Location: Montreal, Quebec
Market Cap: $13.7m (Public)
What the company does: Betterlife develops non-hallucinogenic psychedelic-based therapeutics for the treatment of mental health and neurological disorders. Betterlife’s flagship product is the LSD-based BETR-001, which mimics the medicinal properties of LSD without producing hallucinogenic effects. 

Learn more about Betterlife Pharma on their website.

Founded: 1981
Location: Toronto, Ontario
Market Cap: $13.5m (Public)
What the company does: Psyched Wellness develops a consumer product line of psychedelic-based wellness solutions. Their product, Calm, is the first legal Amanita Muscaria extract available in the USA. 

Learn more about Psyched Wellness on their website.

Founded: 2019
Location: Kelowna, British Columbia
Market Cap: $11.9m (Public)
What the company does: Tryp Therapeutics develops psilocybin-based treatments targeting chronic pain and mental health disorders. Their primary pipeline, TRP-9902, is a psilocybin-based treatment applicable to conditions such as fibromyalgia, binge eating disorder, and hypothalamic obesity. 

Learn more about Tryp Therapeutics on their website.

Founded: 2021
Location: Pittsburgh, Pennsylvania
Market Cap: $11.6m (Private)
What the company does: Mindstate Design Labs is a drug development company that designs psychedelic-initiated altered states of consciousness for mental health therapy. 

Learn more about Mindstate Design Labs on their website.

Founded: 2020
Location: Vancouver, British Columbia
Market Cap: $11.3m (Public)
What the company does: Filament Health develops naturally-derived psychedelic medicines produced through cost-effective methods to increase the global availability of their products. 

Learn more about Filament Health on their website.

Founded: 2020
Location: New York, New York
Market Cap: $11.1m (Private)
What the company does: Reset Pharmaceuticals is a biotechnology company developing commercial-grade psychedelic treatments for patients with life-threatening illnesses like cancer. Reset’s primary focus is using psilocybin-based medicine to treat cancer-related mental health conditions. 

Learn more about Reset Pharmaceuticals on their website.

Founded: 2021
Location: San Francisco, California
Market Cap: $10.5m (Private)
What the company does: Freedom Biosciences develops psychedelic pharmaceuticals with psychoactive compounds such as Ketamine to deliver efficacious treatments to those with mental health disorders. 

Learn more about Freedom Biosciences on their website.

Founded: 2017
Location: Vancouver, British Columbia
Market Cap: $10.4m (Public)
What the company does: Clearmind is using psychedelic-based treatments targeting binge behavior and mental health, including nicotine abuse and depression. Clearmind has developed a new psychoactive compound, MEAI, that produces an alcohol-like experience while decreasing the urge to consume alcohol. 

Learn more about Clearmind Medicine on their website.

Founded: 2019
Location: Vancouver, British Columbia
Market Cap: $9.6m (Public)
What the company does: Braxia Scientific provides treatment for adults with depression, suicidality, and related disorders through ketamine based-treatments. 

Learn more about Braxia Scientific on their website.

Founded: 2020
Location: Toronto, Ontario
Market Cap: $9.4m (Public)
What the company does: Awakn Life Sciences is developing commercial psychedelic therapeutics to treat addiction. They are currently focused on developing treatments for addiction disorders such as gambling disorder, compulsive sexual behavior disorder, and binge eating disorder.

Learn more about Awakn Life Sciences on their website.

Founded: 2020
Location: Toronto, Ontario
Market Cap: $8.4m (Public)
What the company does: PharmaTher produces Ketamine-based products for the treatment of neurotic pain and mental health conditions. Their product line currently consists of the Ketamine Patch, Ketamine IV, and Ketamine Pump.

Learn more about PharmaTher on their website.

Founded: 2019
Location: Toronto, Ontario
Market Cap: $7.7m (Public)
What the company does: Field Trip has designed an in-person Ketamine Assisted Therapy program that targets chronic pain. The 1-year program consists of ketamine therapy, meditation, and wellness support to aid in pain management and increase overall health.

Learn more about Field Trip on their website.

Founded: 2015
Location: La Jolla, California
Market Cap: $7.6m (Private)
What the company does: CB Therapeutics is an innovative bio-manufacturing solution that uses a proprietary yeast platform to accelerate the natural metabolic process in psychedelics. Their consistent approach delivers reliable psychoactive molecules to reputable psychedelic-based companies. 

Learn more about CB Therapeutics on their website.

Founded: 2019
Location: Oxford, Ohio
Market Cap: $5.8m (Public)
What the company does: PsyBio combines biotechnology with psychedelic research to develop psycho-targeted compound treatments for mental and neurological health.

Learn more about PsyBio Therapeutics on their website.

Founded: 2013
Location: Denver, Colorado
Market Cap: $5.7m (Public)
What the company does: Mydecine is a biotechnology company creating innovative psychedelic-based medicine focusing on treatments for post-traumatic stress disorder and nicotine addiction. They leverage their multinational network of medical specialists and strategic partnerships to increase the efficiencies of the drug development process. 

Learn more about Mydecine Innovations Group on their website.

Founded: 2020
Location: Vancouver, British Columbia
Market Cap: $5.6m (Public)
What the company does: Mindcure combines proprietary technology and research capabilities to promote “Mental Wealth” through psychedelic-based treatments. Their flagship product, iSTRYM, is a health software that helps optimize psychedelic-led psychotherapy sessions. 

Learn more about Mindcure on their website.

Founded: 2019
Location: Calgary, Alberta
Market Cap: $5.5m (Private)
What the company does: Psygen Labs is accelerating psychedelic research through the synthesis of psychedelic compounds. Their catalog of database APIs is designed to increase efficiencies in the psychedelic supply chain for drug developers, researchers, and clinicians.

Learn more about Psygen Labs on their website.

Founded: 2018
Location: Copenhagen, Hovedstaden
Market Cap: $5.0m (Private)
What the company does: Octarine Bio is a synthetic biology platform using cannabinoids and psychedelics to develop therapeutics targeting a variety of medical conditions. Their proprietary technology utilizes synthesis, yeast fermentation, and enzymatic derivatization to develop validated pharmaceuticals. 

Learn more about Octarine Bio on their website.

Founded: 2018
Location: Vancouver, British Columbia
Market Cap: $4.9m (Public)
What the company does: Universal Ibogaine utilizes the psychedelic West-African shrub, Ibogaine, to develop psychotherapy treatments for opioids and other addictions. Their treatments aim to manage dopamine and serotonin circuits to influence addiction behavior changes. 

Learn more about Universal Ibogaine on their website.

Founded: 2019
Location: Los Angeles, California
Market Cap: $4.9m (Private)
What the company does: Wake Network develops consumer products for wellness utilizing medicinal and psychedelic mushrooms in combination with genomics-based integrations. 

Learn more about Wake Network on their website.

Founded: 2016
Location: Santa Barbara, California
Market Cap: $4.8m (Private)
What the company does: Bexson BioMedical has developed a wearable on-body drug delivery system for the treatment of pain management. Using a ketamine-based compound, the device was designed to combat the rising opioid crisis fueled by traditional painkillers. 

Learn more about Bexson BioMedical on their website.

Founded:.2016 
Location: Kelowna, British Columbia
Market Cap: $4.7m (Public)
What the company does: Mynd Life Sciences is developing treatments for depressive disorders such as Post-partum Depression in mothers. Their treatments seek to normalize women’s health post-birth through the use of psilocybin-based medicines. 

Learn more about Mynd Life Sciences on their website.

Founded: 2020
Location: Hialeah, Florida
Market Cap: $3.5m (Private)
What the company does: Return Health utilizes psychedelic-based medicine to treat dementia. Their treatments are agonists of the serotonin receptor 5HT-2AR, impacting many brain functions involved in dementia. 

Learn more about Return Health on their website.

Founded: 2021
Location: Vancouver, British Columbia
Market Cap: $3.0m (Private)
What the company does: Clairvoyant Therapeutics is treating those with alcohol use disorder through psilocybin-based therapies. Their therapies include psilocybin drug administration and staged counseling sessions to achieve a paradigm shift in affected patients. 

Learn more about Clairvoyant Therapeutics on their website.

Founded: 2019
Location: Tampa, Florida
Market Cap: $2.6m (Private)
What the company does: Psilera is utilizing natural psychoactive products to build innovative neurological drugs for mental health treatments. Psilera increases the accessibility of psychedelic medicine by making small adjustments to psychoactive compounds to reduce side effects and hallucinations. 

Learn more about Psilera Bioscience on their website.

Founded: 2018
Location: Toronto, Ontario
Market Cap: $2.4m (Private)
What the company does: Diamond Therapeutics develops therapies for neuropsychiatric conditions using psilocybin-based medicines.  These low-dose therapies are designed to be accessible to a broad range of patients through cost-effective options that eliminate side effects. 

Learn more about Diamond Therapeutics on their website.

Founded: 2020
Location: San Diego, California
Market Cap: $1.9m (Private)
What the company does: Mycrodose is a pharmaceutical company developing drug delivery systems for psychedelic microdoses targeting cancer-related conditions, mental health, and cognitive degenerative diseases. 

Learn more about Mycrodose Therapeutics on their website.

Founded: 2020
Location: Homer Glen, Illinois
Market Cap: $1.2m (Public)
What the company does: Wesana Health utilizes data-driven methods to develop psychedelic-based therapies targeting an array of mental health conditions.

Learn more about Wesana Health on their website.

Founded: 2010
Location: Coquitlam, British Columbia
Market Cap: $1.1m (Public)
What the company does: Entheon Biomedical is a biotechnology company developing and commercializing a variety of DMT-based therapeutic products used to treat substance abuse disorders. 

Learn more about Entheon Biomedical on their website.

Founded: 2019
Location: Vancouver, British Columbia
Market Cap: $1.1m (Private)
What the company does: Mindleap is a mobile psychedelic wellness platform that offers consumers psychedelic education, meditations, and coaching to cultivate a comprehensive psychedelic journey.

Learn more about Mindleap on their website.

Founded: 2020
Location: Vancouver, British Columbia
Market Cap: $0.8m (Public)
What the company does: Levitee Labs is seeking to use psychedelic-based treatments to bridge the gap between what the medical system currently provides and what the patients need. Levitee Labs has also implemented an aggressive M&A approach by adding companies such as MONKE Nutra and Ojio to their portfolio to increase their offerings. 

Learn more about Levitee Labs on their website.